Maarten IJzerman

Whole genome sequencing in oncology: using scenario drafting to explore future developments

Michiel van de Ven, Martijn JHG Simons, Hendrik Koffijberg, Manuela A Joore, Maarten J IJzerman, Valesca P Retèl, Wim H van Harten

Journal article  |  2021  |  BMC Cancer

Abstract Background In oncology, Whole Genome Sequencing (WGS) is not yet widely implemented due t..

Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

K Degeling, A Pereira-Salgado, NM Corcoran, PC Boutros, P Kuhn, MJ IJzerman

Journal article  |  2021  |  European Urology Open Science

Early technology assessment of using whole genome sequencing in personalised oncology.

Martijn Simons, Michiel van de Ven, Veerle Coupé, Manuela Joore, Maarten IJzerman, Erik Koffijberg, Geert Frederix, Carin Uyl-De Groot, Edwin Cuppen, Wim van Harten, Valesca Retèl

Journal article  |  2021  |  Expert Review of Pharmacoeconomics & Outcomes Research

INTRODUCTION: Personalized medicine-based treatments in advanced cancer hold the promise to offer substantial health benefits to g..

Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy

Frederik van Delft, Mirte Muller, Rom Langerak, Hendrik Koffijberg, Valesca Retel, Daan van den Broek, Maarten IJzerman

Journal article  |  2021  |  Medical Decision Making

BACKGROUND: Although immunotherapy (IMT) provides significant survival benefits in selected patients, approximately 10% of patient..

Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals

Michiel van de Ven, Hendrik Koffijberg, Valesca Retel, Kim Monkhorst, Egbert Smit, Wim van Harten, Maarten IJzerman

Journal article  |  2021  |  Journal of Molecular Diagnostics

The continued introduction of biomarkers and innovative testing methods makes already complex diagnosis in patients with stage IV ..

A scoping review of studies using observational data to optimise dynamic treatment regimens

Robert K Mahar, Myra B McGuinness, Bibhas Chakraborty, John B Carlin, Maarten J IJzerman, Julie A Simpson

Journal article  |  2021  |  BMC Medical Research Methodology

BACKGROUND: Dynamic treatment regimens (DTRs) formalise the multi-stage and dynamic decision problems that clinicians often face w..

An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic

Koen Degeling, Nancy N Baxter, Jon Emery, Mark A Jenkins, Fanny Franchini, Peter Gibbs, G Bruce Mann, Grant McArthur, Benjamin J Solomon, Maarten J IJzerman

Journal article  |  2021  |  Asia-Pacific Journal of Clinical Oncology

AIM: Decreased cancer incidence and reported changes to clinical management indicate that the COVID-19 pandemic has delayed cancer..

Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening

Hendrik Koffijberg, Koen Degeling, Maarten J IJzerman, Veerle MH Coupe, Marjolein JE Greuter

Journal article  |  2021  |  Value in Health

OBJECTIVES: Metamodeling can address computational challenges within decision-analytic modeling studies evaluating many strategies..

Health Economic Evidence of Point-of-Care Testing: A Systematic Review

Deon Lingervelder, Hendrik Koffijberg, Ron Kusters, Maarten J IJzerman

Journal article  |  2021  |  PharmacoEconomics - Open

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late

Maarten J IJzerman, Jasper de Boer, Arun Azad, Koen Degeling, Joel Geoghegan, Chelsee Hewitt, Frederic Hollande, Belinda Lee, Yat Ho To, Richard W Tothill, Gavin Wright, Jeanne Tie, Sarah-Jane Dawson

Journal article  |  2021  |  Diagnostics

Blood-based liquid biopsies are considered a new and promising diagnostic and monitoring tool for cancer. As liquid biopsies only ..